scholarly journals Exocrinous function of pancreas in Crohn’s disease patients

2009 ◽  
Vol 8 (4) ◽  
pp. 118-125
Author(s):  
V. A. Burkovskaya
Keyword(s):  
Monoclonal Antibodies ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Functional State ◽  
Irritable Colon ◽  
Irritable Colon Syndrome ◽  
Fecal Elastase ◽  
Elastase 1 ◽  
Enzyme Test ◽  
Healthy Persons

The functional state of pancreas in patients with the Crohn’s disease was studied. In feces of patients with CD, irritable colon syndrome, and healthy persons, the daily fat amount was determined by the van de Kamer’s method and fecal elastase-1 was determined using the immune-enzyme test with monoclonal antibodies (EIA system of BioServ Diagnostics, Elastase 1-ELISA, Germany). The fecal elstase-1 level in absolute and relative values in patients with CD decreases statistically confidently as the main disease becomes more severe.

scholarly journals Infliximab: A Review of its use in the Treatment of Pediatric Crohn's Disease

2010 ◽  
Vol 2 ◽  
pp. CMT.S2840
Author(s):  
Arkady Broder ◽  
Joel R. Rosh
Keyword(s):  
Monoclonal Antibodies ◽  
Crohn’S Disease ◽  
Chronic Disease ◽  
Crohn's Disease ◽  
Tumor Necrosis ◽  
Immune Dysregulation ◽  
Necrosis Factor Alpha ◽  
The Past ◽  
Factor Alpha ◽  
Necrosis Factor

The past decade has brought great change to the treatment of pediatric Crohn's disease. The majority of affected patients now receive therapy directed at the underlying immune dysregulation that is associated with this chronic disease. The monoclonal antibodies directed against tumor necrosis factor alpha play an increasing role in such therapy. Infliximab is the prototype of this class of biologic based therapy. This review covers the basic pharmacokinetics of infliximab while reviewing the data on its efficacy in pediatric Crohn's disease patients. Current issues related to infliximab dosing and safety are also reviewed.

Features of a functional state of the liver in children with crohn's disease

2016 ◽  
Vol 78 (6) ◽  
pp. 103-106
Author(s):  
V.S. Berezenko ◽  
◽  
E.N. Tkalik ◽  
M.B. Dyba ◽  
R.V. Mostovenko ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Functional State

scholarly journals Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan

2015 ◽  
Vol 2015 ◽  
pp. 1-4 ◽  
Author(s):  
Michael A. Lane ◽  
Vijay Renga ◽  
Andrew R. Pachner ◽  
Jeffrey A. Cohen
Keyword(s):  
Multiple Sclerosis ◽  
Monoclonal Antibodies ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Jc Virus ◽  
Case Reports ◽  
Ibritumomab Tiuxetan ◽  
Immunomodulatory Therapies

PML caused by John Cunningham (JC) virus is a rare but an increasingly recognized entity. With the advent of newer immunomodulatory therapies with monoclonal antibodies, there is an increasing incidence of PML. Initially concern was restricted to patients treated for multiple sclerosis with natalizumab but more case reports are being reported during treatment for other conditions like Crohn’s disease and lymphoma with agents such as rituximab. We report the case of a 66-year-old woman who developed PML a year after completion of therapy with rituximab, ibritumomab, and bendamustine.

Immunological studies on crohn’s disease V. Enumeration of circulating lymphocytes subsets using monoclonal antibodies

1985 ◽  
Vol 20 (5) ◽  
pp. 431-435 ◽  
Author(s):  
Nobuo Okabe ◽  
Koichi Fujita ◽  
Misao Yamasaki ◽  
Tsuneyoshi Yao ◽  
Sumiaki Tsuru
Keyword(s):  
Monoclonal Antibodies ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Circulating Lymphocytes ◽  
Lymphocytes Subsets

Inflammatory Bowel Disease: Current Pharmacotherapy Issues

1999 ◽  
Vol 12 (6) ◽  
pp. 472-491
Author(s):  
M. Sean Boger ◽  
Ralph H. Raasch
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Monoclonal Antibodies ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Bowel Disease ◽  
Related Quality ◽  
Investigational Therapies ◽  
Inflammatory Bowel ◽  
Active Disease

Inflammatory bowel disease (IBD) includes two idiopathic syndromes, ulcerative colitis and Crohn's disease. In ulcerative colitis, inflammation is limited to the colonic mucosa and submucosa. Crohn's disease may, however, involve the small intestine, all bowel wall layers, and the upper gastrointestinal tract. Because health-related quality of life is significantly impaired during active disease, pharmaceutical care. is important in patient management. Traditional therapy includes 5-aminosalicylates, corticosteroids, and antimicrobial therapy. In steroid-resistant active disease, immunosuppressants (cyclosporine, azathioprine, 6-mercaptopurine, methotrexate) have a role but possess significant toxicity profiles. Current research focuses on the role of inflammatory mediators in IBD. Investigational therapies include monoclonal antibodies to proinflammatory cytokines, inhibitory cytokines, and anti-CD4 monoclonal antibodies.

Sign in / Sign up

Export Citation Format

Share Document